Background--In cardiac hypertrophy and failure, there is a widespread alteration in mRNA splicing, but the role of splice variants in cardiac hypertrophy has not yet been fully elucidated. In this study, we used an exon array to identify novel splice variants associated with cardiac hypertrophy.
C ardiac hypertrophy is an intervening phenomenon that may predispose the heart to cardiac failure. Using molecular biological techniques, many researchers have identified the genes and proteins involved in the pathophysiology of cardiac hypertrophy. [1] [2] [3] [4] [5] [6] Particularly, 3 0 in vitro translation microarray technology has been widely used to examine the expression levels of thousands of genes simultaneously. [7] [8] [9] However, a conventional 3 0 in vitro translation microarray, in which the probes are designated to be near the 3 0 end of each gene, is inadequate for investigating genes encoding multiple splice variants, whereas an exon array, by providing probe sets in all exons, is capable of detecting all transcripts. 10 Splicing analysis may, therefore, provide additional information regarding the pathophysiology of cardiac hypertrophy.
Approximately 74% to 95% of human genes undergo multiple alternative splicing events, 11, 12 more than half of which are regulated in a cell-type-specific, tissue-specific, or developmental manner. 13 A genome-wide study has shown widespread alteration in mRNA splicing in the hearts of patients with heart failure, indicating its involvement in the pathogenesis of cardiac diseases. [14] [15] [16] We performed a global analysis of splice variants in murine hypertrophic hearts using an exon array and identified the mitochondrial tumor suppressor 1 (Mtus1) splice variant associated with cardiac hypertrophy. The Mtus1 gene was first reported as a tumor suppressor gene localized in the mitochondria, 17 and 3 splice variants of the Mtus1 gene have since been reported in mice. 18 Several studies revealed that the Mtus1A variant (corresponding to ATBP50) suppresses ERK phosphorylation, which leads to the inhibition of cell proliferation. [18] [19] [20] It is well established that the ERK pathway plays an essential role in the signaling of cardiac hypertrophy. 6 These findings led us to investigate the role of the Mtus1A variant during cardiac hypertrophy progression. Our findings provide the first evidence that Mtus1A has an inhibitory effect on cardiac hypertrophy.
Methods

Antibodies and Reagents
Phenylephrine (PE; 046K1351), angiotensin II (Ang II; A9525), and anti-FLAG M2 monoclonal antibody (A8592, F1804) were purchased from Sigma-Aldrich (St. Louis, MO). Antibodies against Actin (sc-1615) and donkey anti-goat IgG (sc-2020) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) for Western blotting. Antibodies against phospho-ERK1/2 (#9101S), phospho-MEK (#9121S), MEK (#9122S), p-c-Raf (#9427S), c-Raf (#9422), Histone H3 (#9715), a-tubulin (#2144), and rabbit IgG (#7074S) were purchased from Cell Signaling Technology (Danvers, MA). The antibody against ERK1/2 (V114A) was purchased from Promega (Madison, WI). The antibody against Tom20 (612278) was purchased from BD Biosciences (San Jose, CA). The antibody against glyceraldehy-de3-phosphate dehydrogenase (Gapdh) (HAB374) was purchased from EMD Millipore (Billerica, MA). The antibody against a1 Na, K-ATPase (ab7671) was purchased from Abcam (Cambridge, UK). An anti-Mtus1 polyclonal antibody raised in rabbits targeted a peptide (CSPKRSPTSSAIPFQSPRNSGSFSSP-SISPR) within the C terminus of the protein. The antibodies for immunofluorescence staining of Alexa mouse Fluor 488 (A11029), rabbit Fluor 488 (A11034), rabbit Fluor 546 (A11035), Fluor 568 phalloidin (A12380), and 4 0 ,6-diamidino-2-phenylindole (DAPI) (D1306) were purchased from Invitrogen (Carlsbad, CA).
RNA Isolation and Array Hybridization
Total RNA from myocardial samples was purified using RNeasy MinElute columns (Qiagen, Hilden, Germany). High RNA quality was confirmed in all samples using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). One microgram of total RNA was labeled using the Whole Transcript Sense Target Labeling Assay (Affymetrix, Santa Clara, CA) and hybridized to Mouse Exon 1.0 ST Arrays (Affymetrix) overnight before scanning using an Affymetrix GCS 3000 7G scanner.
Exon Array Analysis
Exon array CEL files were loaded into ArrayAssist software (Stratagene Software Solutions). Probe sets at the core level were summarized using the ExonPLIER algorithm and normalized with antigenomic background probes. For valiance stabilization, the value of 16 was added to the probe set intensity values before transformation to a log 2 scale. Quality analysis confirmed that the data were suitable for assessment. Background noise was detected according to the detection above background algorithm, and probe set signals below the background noise level were filtered out. Probe set level analysis was performed using the ExonPLIER algorithm. Gene expression level analysis was performed using TranscriptPLIER. A splicing index, defined as log 2 (individual exon signal/gene expression level signal), was calculated for all probe sets. If the difference in splicing index between sham and hypertrophic hearts was greater than 1.0 (indicating a fold change ≥2) and statistically significant (P<0.05), the exon was considered to have been spliced in or out during cardiac hypertrophy. Genes with more than 2-fold changes in expression level (P<0.05) were excluded from this study. For efficient functioning of the alternative splicing algorithms, genes with a low expression level (transcription signal <5) in hearts were excluded from the analysis. Finally, the selected genes were inspected in the University of California Santa Cruz (UCSC) genome browser to localize and describe alternative splicing events.
RNA-Seq Library Preparation and Sequencing
Total RNA samples of 2.5 lg each were prepared for RNA-Seq using the Illumina TruSeq RNA Sample Prep Kit v2 (Illumina, San Diego, CA), following the manufacturer's instructions. We assessed the size and purity of cDNA libraries using an Agilent 2100 Bioanalyzer (DNA 1000 kit) and qualified the libraries by quantitative polymerase chain reaction (PCR) using a KAPA library quantification kit (NIPPON Genetics Co, Tokyo, Japan). After denaturation, 15 pmol/L of the libraries was sequenced on an Illumina MiSeq utilizing 75-bp paired-end reads. The sequence data were analyzed using CLC Genomics Workbench (CLC Bio, Aarhus, Denmark). The sequenced reads were mapped to the reference mouse genome (MGSCv37).
Experimental Animal Models
Generation of mice with transverse aortic constriction (TAC)
We subjected C57BL/6J male mice (age, 8 weeks) to TAC or sham operation and measured their hemodynamic parameters as previously reported. 21 Echocardiography was performed using a Vevo 2100 ultrasound system (VisualSonics Inc, Toronto, Canada) equipped with a 30-MHz transducer.
Pharmacologically induced cardiac hypertrophy models C57BL/6J male mice (age, 6 weeks) were infused with PE (75 mg/kg per day), Ang II (1000 ng/kg per minute), or saline using mini-osmotic pumps (Alzet, Cupertino, CA) to induce cardiac hypertrophy. After the hemodynamic parameters were measured, the PE-treated mice were euthanized 7 days after pump implantation, and the Ang II-treated mice at 14 or 28 days.
All experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and were approved by the ethical committee of Osaka University and National Cerebral and Cardiovascular Center.
Subcellular Fractionation
Murine hearts were pulverized under liquid nitrogen and homogenized at 4°C in homogenate buffer (0.25 mol/L sucrose, 20 mmol/L HEPES, 1 mmol/L EDTA, pH 7.4, including a protease inhibitor cocktail). The nuclear fraction of the homogenate was pelleted by centrifugation at 700g for 10 minutes at 4°C. The postnuclear supernatant was further centrifuged at 1000g for 10 minutes at 4°C and the pellet was discarded. The cytosolic fraction was obtained by ultracentrifugation at 120 000g for 1 hour at 4°C. The supernatant was added to 2 mL of each solution (10%, 15%, 20%, 25%, 30%, and 40%), using OptiPrep TM density gradient solution (Sigma). The solutions were then ultracentrifuged at 107 000 g for 13 hours at 4°C using a SW41 Ti swing bucket rotor (Beckman Coulter, CA). After that we were able to obtain the plasma membrane and mitochondrial fractions.
Cell Culture and Treatment
Primary cultures of cardiomyocytes were prepared from the ventricles of 1-day-old Wistar rats, as reported previously. 22 After separation from cardiac fibroblasts, the cardiomyocytes were plated at 75910 4 cell/mL on collagen-coated culture dishes with DMEM containing 10% FCS. For immunofluorescence staining, cardiomyocytes were plated at 20910 4 cell/mL on a collagen-coated 4-well Lab-Tek TM chamber slide. For analysis of the cell surface area, the cells were cultured with DMEM containing 1% FCS 48 hours after plating. After 24-hour incubation with 1% FCS, 100 lmol/L PE was added to the medium, and the cells were stimulated for 48 hours. To evaluate protein phosphorylation, the cells were starved in serum-free DMEM after washing (3 times) with phosphate-buffered saline. Following starvation for 24 hours, 10 lmol/L PE was added to the medium, and the cells were stimulated for 5 minutes. Lowpassage cardiac fibroblasts were used (passage 3).
Small Interfering RNA (siRNA) Design and Transfection
Duplexed RNA oligonucleotides (Stealth RNAi) and RNAi with Alexa Fluor 488 were synthesized by Invitrogen. Three types of Stealth RNAi oligonucleotides were tested for their ability to knockdown endogenous Mtus1.
The sequences of siRNAs are as follows (sense strands): Mtus1A-36, 5 0 -UCACGUCCGCCUAACCGCCAAGGGA; Mtus1A-47, 5 0 -UUUCGAAGCAGUCCCUUGGCGGUUA; and Mtus1A-75, 5 0 -UUUCCUGAGCCCAGAAGGAAGCCGG.
As a negative control, Stealth RNAi Negative Control Med GC Duplex #2 (46-5372) was purchased from Invitrogen. Six hours after isolating neonatal rat cardiomyocytes, the cells were transfected with siRNAs (20 nmol/L) using Lipofectamine TM RNAiMAX. The proteins were extracted 72 hours after transfection. We selected Mtus1A-75 because this was the most effective siRNA to knockdown both the mRNA and the protein levels of Mtus1A.
Construction of Adenovirus Vectors
Murine
Mtus1A (NM_001005865) and Mtus1C (NM_001005863) were amplified using PCR from a murine heart cDNA library and inserted into pENTR/D-TOPO vectors using Gateway technology (Invitrogen). We also generated Nterminal deletion mutants of the Mtus1A variant: D17, D24, D27, and D33 AA with C-terminal FLAG tagging. Adenoviral constructs were generated using the ViraPower Adenoviral Expression System (Invitrogen). The supplied pAd/CMV/V5-DEST/lacZ (Invitrogen) was used as a control. Twenty-four hours after plating on dishes, the cardiomyocytes were transfected with each adenoviral vector at a multiplicity of infection of 20. The adenovirus-mediated overexpression of murine Mtus1A was inhibited with siRNAs targeting rat Mtus1A. These samples were transfected with the adenoviral vector at a multiplicity of infection of 80 to adjust Mtus1A expression.
The 2A Peptide Expression Vectors
The T2A (Thosea asigna virus 2A) sequence was inserted between the sequences encoding Mtus1A (FL, D27 AA) and emGFP. The Mtus1A-T2A-emGFP sequences were cloned into pENTR/D-TOPO vectors using Gateway technology (Invitrogen). Adenovirus constructs were then generated using the ViraPower Adenoviral Expression System (Invitrogen).
T2A sequence: 5 0 -GAGGGCAGAGGAAGTCTTCTAACATGC GGTGACGTGGAGGAGAATCCCGGCCCT-3 0 .
Incorporation of [ 3 H]-Leucine
Protein synthesis in cardiomyocytes was evaluated according to the amount of [ 3 H]-leucine incorporated into cells. Following culture for 24 hours with DMEM containing 1% FCS, 1 lCi/mL [ 3 H]-leucine was added to the medium with or without 100 lmol/L PE for a further 48 hours. After washing (2 times) with PBS, the cells were harvested using trypsin and attached to glass filter mats using a microharvester, and radioactivity was measured using a liquid scintillation counter (Wallac b-plate, Turku, Finland).
Real-Time PCR Analysis of mRNA Levels
Total RNA was extracted from the samples using TRIzol reagent (Invitrogen). cDNA was generated by the reverse transcription of 2 lg total RNA using Omniscript RT kit (Qiagen). Real-time PCR was performed with TaqMan technology using a StepOne Real-Time PCR system (Applied Biosystems, Carlsbad, CA). Variant-specific and common TaqMan probes and primers for Mtus1 were synthesized by Applied Biosystems. TaqMan probes and primers for Nppa, eukaryotic 18S rRNA, and Gapdh were also purchased from Applied Biosystems. Data were normalized to those of 18S rRNA or Gapdh, and relative expression levels were calculated using an arithmetic comparative 2 ÀDDCt method.
TaqMan probes and primers were designed to detect the Mtus1 exon 15 to 16 boundary (common exon); the Mtus1A exon 7 to 8 boundary; the Mtus1B exon 4 to 5 boundary; and the Mtus1C over 1 to 2 boundary.
Reactive Oxygen Species (ROS) Measurement
Cardiomyocytes were cultured and then transfected with adenovirus vectors (LacZ-2A-emGFP, full-length Mtus1A-2A-emGFP, D27-2A-emGFP) or siRNA with Alexa Fluor 488 (si control, si Mtus1A). Following starvation, the cells were incubated with 5 lmol/L MitoSOX Red (Invitrogen, M36008) for 10 minutes in HBSS/Ca/Mg medium (Invitrogen). ROS production in cardiomyocytes was observed following exposure to 10 lmol/L PE in serum-free DMEM without phenol red (Wako, 040-30095).
Western Blot
For total cellular protein extraction, cells were washed with cold PBS and lysed with lysis buffer (1% NP-40, 150 mmol/L NaCl, 20 mmol/L Tris [pH 7.5], 2 mmol/L EDTA, 50 mmol/L NaF and 1 mmol/L Na 3 VO 4 , including a protease inhibitor cocktail). An equal amount of protein per well was loaded onto 7.5% to 10% SDS-PAGE gels and transferred onto nitrocellulose membranes. The Bio-Rad ChemiDoc XRS system (Bio-Rad Laboratories, Inc, Hercules, CA) was used for chemiluminescence imaging, and the band density was quantified using Bio-Rad Quantity One 1-D Analysis software (Bio-Rad Laboratories).
Immunofluorescence Staining
Neonatal rat cardiomyocytes were incubated with 500 lmol/ L of MitoTracker Red (Invitrogen, M-7512) for 30 minutes. The cells were then fixed with 4% paraformaldehyde at room temperature for 10 minutes, washed (twice) using PBS, and permeabilized with 0.2% Triton-X/PBS (room temperature, 10 minutes). After blocking with 10% FCS/PBS buffer for 1 hour at room temperature, the cells were incubated with Mtus1 antibody (1:500), anti-FLAG M2 monoclonal antibody (1:500), and a-tubulin (1:500) for 1 hour at 4°C. The cells were washed twice using PBS, and incubated with the corresponding secondary antibodies for 1 hour at 4°C (Alexa Fluor 488-, Alexa Fluor 546-, and Alexa Fluor 568-conjugated antibodies, 1:500). After washing sufficiently with PBS, the cells were observed using a fluorescence microscope. The following excitation and emission filters were used: GFP, Ex/Em=489/510 nm; MitoTracker Red, Ex/Em=578/ 598 nm; and MitoSOX Red, Ex/Em=533/574 nm. Images were visualized using an Olympus Power IX-81 inverted fluorescence microscope (Olympus, Tokyo, Japan) or FLUO-VIEW FV10i confocal microscope (Olympus). The images obtained using IX-81 and FLUOVIEW FV10i microscopy were analyzed using MetaMorph (MDS Analytical Technologies, Sunnyvale, CA) and FV10-ASW software (Olympus), respectively. The cell surface area was measured using Scion Image (Scion Corporation, Houston, TX).
Immunohistochemical Staining
Heart samples were fixed in 4% paraformaldehyde overnight at 4°C followed by paraffin embedding. Sections were deparaffinized and rehydrated, and antigen retrieval was performed using EDTA (pH 9.0) in a 95°C water bath for 20 minutes. To block endogenous peroxidase activity, the sections were immersed in 3% hydrogen peroxide in methanol for 15 minutes and then incubated overnight with polyclonal Mtus1 antibody (1:500) in ChemMate Antibody Diluent (DakoCytomation, Tokyo, Japan) at 4°C. After rinsing with Tris Buffered Saline with Tween 20, the sections were labeled with horseradish peroxidase-conjugated anti-rabbit IgG for 30 minutes and then visualized with DAB+ (DakoCytomation, Glostrup, Denmark).
The sections were also stained with hematoxylin-eosin for morphological evaluation and Sirius red to evaluate fibrosis. Images were visualized on a BZ-9000 Biorevo all-in-one fluorescence microscope (Keyence Corp, Osaka, Japan), and the cross-sectional area was measured in more than 100 randomly selected cardiomyocytes using BZ-II Analyzer software (Keyence Corp).
Generation of Cardiac-Specific Mtus1A Transgenic Mice
The Mtus1A (NM_001005865) transgene was cloned downstream of the murine a-myosin heavy chain (a-MHC) promoter. The purified DNA used in the microinjection was released from the vector backbone. The transgenic founders were produced by pronuclear injection, using standard methods. Mtus1A transgenic (TG) mice were originally derived from the C57BL/6J Jcl background. Line 13 male mice (age, 6 weeks) were used for further study.
Real-Time PCR-Based Copy Number Assay
The genomic DNA (gDNA) was isolated from mouse tail by the standard phenol-chloroform method. The gDNAs were diluted to a concentration of 5 ng/lL and then mixed with 2x TaqMan Genotyping Master Mix and TaqMan primers and probes for Mtus1 and Tfrc (Applied Biosystems). The number of transgene copies was calculated using an arithmetic comparative 2 ÀDDCt method.
Statistical Analysis
This study was designed to examine the inhibitory effects of Mtus1A against cardiac hypertrophy using several parameters for hypertrophy. Statistical analyses were performed to compare the splicing index, the expression of Mtus1, the left ventricular posterior wall thickness (LVPWT), cell size, protein synthesis, ERK activation, and ROS production between controls and intervention groups.
All tests for statistical significance were two-sided. Student t test and Mann-Whitney U test were used to study differences between groups. All data are expressed as meanAESD.
Results
Global Analysis of Exon Expression Levels in Hypertrophic Hearts
To investigate the role of alternative splicing in the pathogenesis of cardiac hypertrophy leading to heart failure, we induced cardiac hypertrophy by TAC for 8 weeks (Table S1 ). We performed global analysis of exon and gene levels in these hearts, using the Mouse Exon 1.0 ST Array. Of the 222 710 probe sets mapped on 17 705 genes, we filtered out those with signal levels below the background noise level, leaving 161 159 probe sets for 10 766 genes ( Figure 1A ). In 3677 (2.28%) of these remaining probe sets, the exon level changed in the TAC hearts to more than double the level in the control hearts. We selected 756 genes that contained at least 1 of these 3677 probe sets and then separately performed splicing and genelevel analysis. Subsequently, to normalize and quantify the exon expression level, we calculated the splicing index, enabling us to compare the splicing analysis between the 2 groups. 10 We classified these 756 genes into 4 groups according to whether the observed changes in the gene expression level and/or the splicing pattern were greater than 2-fold, with P<0.05. We identified 113 genes with significant changes in the splicing pattern but not in the expression level; 112 genes with changes in the expression level but not in the splicing pattern; 140 genes with changes in both the expression level and splicing pattern; and 391 genes without changes in the expression level and splicing pattern ( Figure S1 ).
Identification of Mtus1 as a Spliced Gene in Hypertrophic Hearts
In this study, we focused on the spliced genes that are incapable of being detected using 3 0 in vitro translation microarray. Thus, we narrowed our investigation to the 113 genes with significant changes in the splicing pattern but no change in the gene expression levels when comparing the TAC and control hearts. We then excluded 67 genes with a low expression level in both the control and TAC hearts, leaving 46 candidate genes (Table S2) .
Eventually, we focused on the Mtus1 gene, the only gene whose splice variants were registered in the NCBI RefSeq database ( Figure 1A ). The Mtus1 gene is located on chromosome 8 and contains 16 exons. The Mtus1 gene encodes 3 splice variants that differ in the 5 0 exon: Mtus1A (NM_001005865) utilizes exons 7 to 16; Mtus1B (NM_001005864) utilizes exons 4 to 16, lacking exon 7; and Mtus1C (NM_001005863) utilizes exons 1 to 16, lacking exons 4 and 7 ( Figure 1B ). The exon array indicated significant differences in the splicing indices mapped on exons 2 to 7. The splicing indices mapped on exons 2 to 6 were downregulated in TAC hearts, whereas the splicing index mapped on exon 7 was upregulated. The splicing indices mapped on exons 8 to 16 were unchanged ( Figure 1B) . These results indicate that Mtus1A is upregulated; but both Mtus1B and Mtus1C are downregulated in hypertrophic hearts. The RNA-Seq read coverage of each exon was similar to the exon array data and showed no other Mtus1 variants existed ( Figure S2 ).
Validation of Mtus1 Splice Variant Expression Using Real-Time PCR
Real-time PCR showed no difference between the control and TAC hearts in the gene expression level of Mtus1 ( Figure 1C ). In contrast, we observed a significant increase in the expression level of Mtus1A mRNA and a significant decrease in the level of Mtus1C mRNA in the TAC hearts ( Figure 1D ). The results from real-time PCR analysis were in accordance with the exon array data. Mtus1B was not detected in the hearts.
Mtus1A Protein Level Increased in the Hypertrophic Hearts
To investigate the levels of both Mtus1A and Mtus1C proteins, we generated a Mtus1A polyclonal antibody that recognizes an epitope in the C-terminal region and can detect all Mtus1 variants. We detected the Mtus1A protein as 2 bands between 40 and 50 kDa and detected Mtus1C as a 180-kDa band on Western blots. The Mtus1A and Mtus1C protein levels were significantly increased and decreased, respectively, in the TAC hearts (Figure 2A and 2B ). Next, we examined the tissue distribution pattern of each Mtus1 variant using real-time PCR and observed a high expression level of Mtus1A mRNA in the heart, lung, and brain; tissue-specific expression of Mtus1B mRNA in the brain; and ubiquitous expression of Mtus1C mRNA ( Figure S3 ). To determine the heart cells in which Mtus1 was highly expressed, we detected Mtus1 protein expression in the sham-operated and TAC hearts using immunohistochemical staining. The Mtus1 protein was observed in the myocardial cells but not in the fibrotic lesions ( Figure 2C ). We also confirmed that the Mtus1A protein was expressed only in cardiomyocytes and not in cardiac fibroblasts from neonatal rat hearts ( Figure 2D ). The expression level of the Mtus1C protein was significantly lower than that of Mtus1A ( Figure 2B ). This result suggested an important role for Mtus1A in the heart and led us to focus our investigation on the Mtus1A variant.
An Association Between Cardiac Hypertrophy and Mtus1A Expression
To investigate the association between cardiac hypertrophy and Mtus1A expression, we examined the expression levels of myocardial Mtus1A in mice at 1, 4, and 8 weeks following TAC. We were able to obtain hypertrophy models with and without heart failure by TAC induction for 8 weeks. We defined heart failure as both the presence of lung edema and reduced ejection fraction. Compared with sham-operated groups at the corresponding weeks, Mtus1A expression gradually increased in a time-dependent manner, and the level increased as the LVPWT increased. At 8 weeks, the expression of Mtus1A in the hypertrophy models without heart failure significantly increased, compared with the heart failure models ( Figure 3A and 3B) . These results imply that the Mtus1A expression level increases in response to cardiac hypertrophy. We confirmed that the Mtus1A expression level was associated with the degree of cardiac hypertrophy in other models induced by Ang II and PE ( Figure 3C and 3D).
Mtus1A Is an Inhibitory Factor for Cardiomyocyte Hypertrophy
We found that adenovirus-mediated Mtus1A overexpression suppressed both cell size and protein synthesis in cardiomyocytes (Figure 4 through 4D) . In contrast, siRNA knockdown of Mtus1A increased both cell size and protein synthesis in cardiomyocytes ( Figure 4E through 4H) .
Furthermore, we examined whether the Mtus1A protein inhibited cardiomyocyte hypertrophy induced by PE. Mtus1A overexpression diminished the PE-stimulated increase in both cell size and protein synthesis in cardiomyocytes ( Figure 4A through 4D). Conversely, Mtus1A knockdown enhanced PEinduced cardiomyocyte hypertrophy ( Figure 4E through 4H) . These results indicate that Mtus1A has an inhibitory effect on cardiomyocyte hypertrophy.
Mtus1A Modulates the ERK Signaling Cascade
To confirm the cellular mechanism for the inhibitory effect of Mtus1A on cardiomyocyte hypertrophy, we investigated the ERK signaling cascade responsible for cardiac hypertrophy. Mtus1A overexpression attenuated the PE-induced phosphorylation of c-Raf, MEK, and ERK ( Figure 5A ). We observed an augmentation of PE-induced phosphorylation of c-Raf, MEK, and ERK, following Mtus1A knockdown with siRNA ( Figure 5B) . Moreover, the enhanced PE-induced activation of ERK signaling following knockdown of Mtus1A was attenuated by Mtus1A overexpression (Figure 5C and 5D).
Mitochondrial Localization of Mtus1A
We determined the subcellular localization of Mtus1 and detected the Mtus1A protein predominantly in the mitochondria of murine hearts. The Mtus1C protein showed a different expression pattern, as it was expressed in the nucleus and cytosol ( Figure 6A and 6B) . We next examined the localization of Mtus1 in neonatal rat cardiomyocytes, overexpressing the Mtus1 variants. This confirmed the localization of Mtus1A in mitochondria and Mtus1C in microtubules ( Figure S4 ). Subsequently, we examined how Mtus1A is targeted to the mitochondria. The protein sequence analysis by MITOPROT II predicted that Mtus1A has a mitochondrial targeting sequence in the exon 1 region. Therefore, we constructed 4 deletion mutants of Mtus1A (D17, D24, D27, and D33), designed by targeting arginine residues in exon 1, and overexpressed these mutants using the adenovirus vector ( Figure 7A ). Full-length (FL), D17 and D24 Mtus1A mutants were mainly detected in the mitochondria. D27 and D33 mutants were exclusively detected in the cytosol ( Figure 7B ). These results clarified that Mtus1A protein is translocated to the mitochondria with a mitochondrial targeting sequence in exon 1.
To examine the nature of 2 distinct bands of Mtus1A in Western blots, we expressed Mtus1A with a C-terminal FLAG tag. We detected 2 bands with the anti-FLAG antibody ( Figure S5 and was not localized in the mitochondria (data not shown).
The addition of the FLAG tag to the N-terminus of Mtus1A may impair cleavage in the mitochondria, resulting in only the upper band being detected.
Mitochondrial Mtus1A Reduced Cardiomyocyte Hypertrophy
The overexpression of D17 and D24 Mtus1A mutants suppressed cell size but the overexpression of D27 and D33 mutants did not ( Figure 7C) . Moreover, the overexpression of D17 and D24 Mtus1A mutants attenuated PE-induced phosphorylation of c-Raf, MEK, and ERK ( Figure 7D ). These results indicate that mitochondrial Mtus1A plays a central role in the regression of cardiomyocyte hypertrophy.
Mtus1A Suppresses Mitochondrial ROS Production
We investigated how Mtus1A modulates ERK signaling in cardiomyocytes. Induction of mitochondrial ROS is known to be 1 of the key factors for the progression of cardiac hypertrophy through the stimulation of Ras/Raf/MEK/ERK signaling. 23, 24 We overexpressed Mtus1A protein using 2A peptide expression vectors ( Figure S6 ). Cardiomyocytes overexpressed with Ad-LacZ-2A-emGFP generate significant amounts of ROS after PE treatment. Overexpression of Mtus1A protein in mitochondria, using Ad-FL-Mtus1A-2A-emGFP, reduced PE-induced ROS production. This reduction of ROS production by Mtus1A overexpression in mitochondria was abolished by inhibiting the translocation of Mtus1A to the mitochondria using Ad-D27-Mtus1A-2A-emGFP ( Figure 8A and 8C ). We confirmed that knockdown of Mtus1A in mitochondria enhanced PE-induced ROS production ( Figure 8B and 8D) . These results implied that Mtus1A inhibits cardiac hypertrophy through the reduction of ERK signaling activated by ROS production.
Cardiac-Specific Overexpression of Mtus1A Inhibits Cardiac Hypertrophy In Vivo
To determine whether Mtus1A regulates cardiac hypertrophy in vivo, we generated TG mice overexpressing Mtus1A driven by the a-MHC promoter ( Figure 9A ). We established the 3 lines of TG mice and observed the upregulation of Mtus1A in their hearts ( Figure S7 and Figure 9B ). No differences were observed in blood pressure, heart rate, and body weight between the Mtus1A TG and wild-type (WT) mice. However, Mtus1A TG mice showed reductions in the heart-to-body-weight ratio, LVPWT, fractional shortening, and cross-sectional area of cardiomyocytes ( Figure 9C , 9D, 9F through 9K and Table S3 ). We also investigated whether Mtus1A overexpression in the heart could inhibit cardiac hypertrophy induced by TAC. We observed that TAC-induced increase in LVPWT was reduced and the cell surface area was also suppressed in the Mtus1A TG mice (Figure 9C , 9D, and 9F through 9H). The extent of LV fibrosis after TAC was not significantly different between the TG and WT mice (WT 9.3AE0.1% versus TG 8.8AE0.8%, P=0.47) ( Figure 9E ). LV systolic function was significantly impaired in Mtus1A TG mice after TAC ( Figure 9F and Videos S1 through S4).
We further investigated whether Mtus1A overexpression inhibits PE-induced cardiac hypertrophy. We observed that the PE-induced increase in LVPWT diminished in the Mtus1A TG mice and that the cell surface area increased to 143% and 111% in the WT and Mtus1A TG mice, respectively ( Figure 9I through 9K). These results indicated that Mtus1A attenuated cardiac hypertrophy.
Discussion
Here global analysis of an exon array identified the Mtus1A variant as a novel regulator of cardiac hypertrophy based on the following evidence: (1) Mtus1A expression increased with the extent of cardiac hypertrophy; (2) Mtus1A expressed in the mitochondria reduced PE-induced c-Raf/MEK/ERK phosphorylation, resulting in a decrease in both protein synthesis and the size of cardiomyocytes; (3) Mtus1A suppressed mitochondrial ROS production following PE stimulation in the mitochondria; and (4) cardiac-specific Mtus1A TG mice showed LV wall thinning, LV dysfunction, and reduced hypertrophic response to pressure overload and PE treatment. The cells were starved for 24 hours and stimulated with 10 lmol/L of PE. ROS production was visualized using MitoSOX (red fluorescence) at the indicated time intervals. B, Real-time detection of mitochondrial ROS production after knockdown of Mtus1A in living cardiomyocytes, following stimulation with PE. Cardiomyocytes were transfected with Alexa 488-labeled small interfering (si) control or si Mtus1A for 64 hours. After starvation, ROS production was visualized following stimulation with PE as in (A). C and D, Quantification of ROS production at 5 minutes after stimulation with PE. Fluorescence intensities of ROS within the region of interest were measured (n=50 cells in each group). Images were visualized using a FLUOVIEW FV10i confocal microscope (scale bar: 30 lm). **P<0.01 vs each control (PEÀ), or as indicated; † † P<0.01 vs Ad-LacZ without PE or si control without PE.
Seibold et al identified Mtus1 as a tumor suppressor gene localized in the mitochondria. 17 Reduced expression levels of Mtus1 are associated with poor prognosis in human tumors, eg, pancreatic, 17 hepatocellular, 25 and colon tumors. 26 The overexpression of Mtus1A inhibits ERK phosphorylation and tumor cell line proliferation. 20, 27 These observations strongly support our finding that Mtus1A attenuates cardiac hypertrophy through ERK signaling reduction.
Mtus1A was also identified as a protein capable of interacting with the C-terminal end of the AT2 receptor (also called AT2 receptor-interacting protein 1, ATIP1), using a yeast 2-hybrid system involving in ERK signaling. 18, 19 The AT2 receptor is expressed in the cell membrane; however, the Mtus1A protein is reported to be localized in either the mitochondria 17 or the Golgi apparatus. 18 We also showed that Mtus1A was localized in the mitochondria of neonatal rat cardiomyocytes. Fujita et al demonstrated that pretreatment with the AT2 receptor-selective antagonist PD123319 did not affect ERK phosphorylation in systemic ATIP (Mtus1A) TG mice, 28 suggesting the existence of an AT2 receptorindependent mechanism of Mtus1A that suppresses ERK signaling in cardiac hypertrophy. Mitochondria, where Mtus1A is mainly expressed, are the main source of ROS production. 29 Mitochondrial ROS production is activated by hypertrophic stimuli, such as G protein-coupled receptor agonists and pressure overload, [30] [31] [32] and induces cardiac hypertrophy through Ras/Raf/MEK/ERK signaling stimulation. 24 This evidence strongly supports our hypothesis that the inhibitory effect of Mtus1A on cardiac hypertrophy is because of the suppression of ROS production.
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Actin Cardiac hypertrophy is caused by various stimuli, such as Ang II, PE, isoproterenol, and mechanical stress. These stimuli activate hypertrophic cascades via MEK/ERK, PI3K/Akt, and calcineurin-NFAT cascades, following the activation of transcription factors. MEK/ERK signaling, but not PI3K/Akt signaling, is activated in TAC hearts. 33 MEK protein overexpression in murine hearts induces cardiac hypertrophy. 6 Thus, MEK/ERK signaling is vital in cardiac hypertrophy, and MEK/ ERK signaling modulation is a potential therapeutic target for cardiac hypertrophy. Recently, a few molecules, such as Carp and Erbin, have been reported to suppress cardiac hypertrophy through ERK signaling inhibition. 33, 34 Song et al reported that Carp overexpression reduced cardiac hypertrophy, but the function of endogenous Carp on cardiac hypertrophy remains unclear. 33 Rachmin et al reported that Erbin expression is reduced in hypertrophic hearts, and Erbin knockout mice exhibited cardiac hypertrophy. 34 Unlike Erbin, we first identified the splice variant induced by cardiac hypertrophy, finding that this variant suppresses ERK signaling activated in a cardiac hypertrophic state.
Recently, Zuern et al revealed that systemic Mtus1 knockout mice, lacking all splice variants, exhibited renal disease, lymphoid hyperplasia, and cardiac hypertrophy. 35 This cardiac phenotype agreed with the present observation; however, because renal diseases are usually associated with cardiac hypertrophy, it is still unclear whether Mtus1 ablation is directly related to cardiac hypertrophy. Moreover, the authors did not clarify which variants affected those phenotypes. In this study, using cardiac-specific Mtus1A TG mice, we showed that the Mtus1A variant is directly related to cardiac hypertrophy. Furthermore, we showed that Mtus1A directly suppresses cardiomyocyte hypertrophy through ERK signaling reduction. Therefore, the present study can be regarded as the first report elucidating the pathophysiological role of Mtus1A in the heart.
Cardiac-specific ERK2 deletion mice exhibited a reduced hypertrophic response to pressure overload and deterioration of LV function. 36 These findings are consistent with our data in Mtus1A TG mice. Consistent with the result in ERK2 knockout mice, the heart-to-body-weight ratio tended to be higher in Mtus1A TG mice after TAC; however, there was no statistically significant difference in the heart to body weight ratio between these and WT mice.
Here we showed that Mtus1A overexpression attenuates cardiac hypertrophy and adversely affects cardiac function. It is believed that there are 2 aspects to cardiac hypertrophy: adaptive and maladaptive phases. [37] [38] [39] Adaptive cardiac hypertrophy represents a physiological response to increased Figure 9 . Continued workloads, which enables an increase in cardiac contractility. However, prolonged and excessive hypertrophy leads to a maladaptive phase, resulting in heart failure. TAC-induced cardiac hypertrophy is an adaptive response to pressure overload. 40 Mtus1A activation may inhibit adaptive hypertrophy, since we observed that Mtus1A overexpression reduced both cardiac hypertrophy and function. Thus, further investigation into the nature of cardiomyocytes with and without Mtus1A activation may reveal differences between adaptive and maladaptive cardiac hypertrophy. We performed genome-wide exon-level analysis and identified the Mtus1A variant as a novel regulator of cardiac hypertrophy. Elucidation of the splicing mechanism of Mtus1 could aid the development of novel treatments for cardiac hypertrophy.
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Figure S5
Video S1.
Echocardiography of a wild type (WT) mouse at 4 weeks after sham operation.
Video S2.
Echocardiography of a mitochondrial tumor suppressor 1 A (Mtus1A) transgenic (TG) mouse at 4 weeks after sham operation.
Video S3.
Echocardiography of a wild type (WT) mouse at 4 weeks after transverse aortic constriction (TAC).
Video S4.
Echocardiography of a mitochondrial tumor suppressor 1A (Mtus1A) transgenic (TG) mouse at 4 weeks after transverse aortic constriction (TAC).
